Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells.
暂无分享,去创建一个
A. Hida | S. Yamasaki | T. Nakashima | K. Migita | K. Eguchi | Y. Kawabe | T. Origuchi | A. Kawakami | N. Matsuoka | S. Urayama | T. Aoyagi | I. Furuichi | M. Nakashima | M. Tsuboi
[1] S. Nagataki,et al. Increased population of high fluorescence 1F7 (CD26) antigen on T cells in synovial fluid of patients with rheumatoid arthritis. , 1996, The Journal of rheumatology.
[2] S. Nagataki,et al. Inhibitory effect of clarithromycin on costimulatory molecule expression and cytokine production by synovial fibroblast‐like cells , 1996, Clinical and experimental immunology.
[3] S. Nagataki,et al. Increase in adhesion molecules on CD4+ cells and CD4+ cell subsets in synovial fluid from patients with rheumatoid arthritis. , 1994, The Journal of rheumatology.
[4] G. Zlabinger,et al. Specific down-regulation of proliferative T cell alloresponsiveness by interference with CD2/LFA-3 and LFA-1/ICAM-1 in vitro. , 1994, Journal of immunology.
[5] S. Nagataki,et al. Immunolocalization of Adhesion Molecules in Rheumatoid and Osteoarthritic Synovial Tissues , 1993 .
[6] G. Panayi,et al. Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. , 1993, Annals of the rheumatic diseases.
[7] J. Gribben,et al. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. , 1993, Science.
[8] L. Lanier,et al. B70 antigen is a second ligand for CTLA-4 and CD28 , 1993, Nature.
[9] K. Tanaka,et al. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 4th communication: inhibitory effect on the production of interleukin-1 and interleukin-6. , 1992, Journal of pharmacobio-dynamics.
[10] R. Kitamura,et al. Pharmacological studies on 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one (T-614), a novel antiinflammatory agent. 3rd communication: the involvement of bradykinin in its analgesic actions. , 1992, Journal of pharmacobio-dynamics.
[11] K. Eguchi,et al. Bucillamine inhibits T cell adhesion to human endothelial cells. , 1992, The Journal of rheumatology.
[12] P. Linsley,et al. Differential costimulatory effects of adhesion molecules B7, ICAM-1, LFA-3, and VCAM-1 on resting and antigen-primed CD4+ T lymphocytes. , 1992, Journal of immunology.
[13] K. Matsushima,et al. Elevation of interleukin-8 (IL-8) levels in joint fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints. , 1991, Lymphokine and cytokine research.
[14] K. Eguchi,et al. Phenotypic characteristics of T cells interacted with synovial cells. , 1991, The Journal of rheumatology.
[15] P. Linsley,et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation , 1991, The Journal of experimental medicine.
[16] E. Clark,et al. The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells , 1991, The Journal of experimental medicine.
[17] L. Davis,et al. Accessory Cell Signals Involved in T‐Cell Activation , 1990, Immunological reviews.
[18] Timothy A. Springer,et al. Adhesion receptors of the immune system , 1990, Nature.
[19] F. Epstein,et al. Rheumatoid arthritis. Pathophysiology and implications for therapy. , 1990, The New England journal of medicine.
[20] T. Rème,et al. T cell receptor expression and activation of synovial lymphocyte subsets in patients with rheumatoid arthritis. Phenotyping of multiple synovial sites. , 1990, Arthritis and rheumatism.
[21] J. Dayer,et al. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. , 1990, Arthritis and rheumatism.
[22] K. Migita,et al. Phenotypic characterization of lymphocytes infiltrating synovial tissue from patients with rheumatoid arthritis: analysis of lymphocytes isolated from minced synovial tissue by dual immunofluorescent staining. , 1990, The Journal of rheumatology.
[23] P. Scuderi,et al. Characteristics of tumor necrosis factor production in rheumatoid arthritis. , 1989, Cellular immunology.
[24] T. Hirano,et al. Constitutive production of interleukin 6/B cell stimulatory factor-2 from inflammatory synovium. , 1989, Clinical immunology and immunopathology.
[25] G. Firestein,et al. Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. , 1989, The Journal of clinical investigation.
[26] P. Guerne,et al. Synovium as a source of interleukin 6 in vitro. Contribution to local and systemic manifestations of arthritis. , 1989, The Journal of clinical investigation.
[27] T. Hirano,et al. Excessive production of interleukin 6/B cell stimulatory factor‐2 in rheumatoid arthritis , 1988, European journal of immunology.
[28] F. Houssiau,et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. , 1988, Arthritis and rheumatism.
[29] N. Miyasaka,et al. Augmented interleukin-1 production and HLA-DR expression in the synovium of rheumatoid arthritis patients. Possible involvement in joint destruction. , 1988, Arthritis and rheumatism.
[30] M. Vadas,et al. The detection and initial characterization of colony-stimulating factors in synovial fluid. , 1988, Clinical and experimental immunology.
[31] Keiichi Tanaka,et al. Pharmacological studies on T-614, a novel antiinflammatory agent: effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/I mice , 1993 .
[32] J. Nunley,et al. Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. , 1989, Arthritis and rheumatism.